Search

Displaying results 3301 - 3310 of 4575 in total
  1. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  2. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.

  3. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and m...

  4. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer

  5. Drug

    Eperisone

    go.drugbank.com/drugs/DB08992
    Investigational

    It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.

  6. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    It is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim.

  7. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    Aceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. It has also been studied in the treatment of presbyopia, a common age-related vision loss where the crystalline le...

  8. Drug

    rsPSMA Vaccine

    go.drugbank.com/drugs/DB06361
    ApprovedWithdrawn

    Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases. rsPSMA Vaccine is a subunit vaccine...

  9. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  10. Drug

    MRK-003

    go.drugbank.com/drugs/DB17015
    Experimental

    MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]